First, the Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial (NCT02065791) examined the effects of 100 mg canagliflozin compared with placebo in patients with type 2 diabetes mellitus (T2DM) and albuminuric kidney disease [estimated glomerular filtration rate (eGFR) 30–90 ml/min/1.73 m2 and a urine albumin:creatinine ratio (UACR) >300–≤5000 mg/g]. Here, ALB is linked to diabetes mellitus.